CREATING CURES FROM COMPLEXITY

Solutions for Viral Research and Discovery

l

l

l

l

l

l

l

ll

l

The discovery of antivirals and vaccines has revolutionized medicine and saved billions of children from diseases such as polio and smallpox. But the high mutation rates and the existence of animal reservoirs contribute to the emergence of new pathogenic viruses with epidemic or pandemic potential. Simply put, we’re far from fully understanding and being able to entirely control viral diseases and their outbreaks.

That’s why understanding viral diseases and translating research findings into better vaccines and treatments are at the core of what we do. Our solutions help researchers:

n Study virus genomes and understand mutations

n Detect viruses and measure replication or efficiency of neutralization

n Identify new drugs targets – either viral or host-cell derived

n Repurpose drugs or discover new antiviral treatments

n Characterize immune responses against viruses

n Identify potent vaccine candidates or adjuvants

FAST TRACKING ANSWERSTO VIRAL DISEASES

l

l

l

l

l

l

l

ll

l

UNDERSTANDINGVIRAL GENOMICSViral genomes exhibit enormous diversity in their makeup: the majority are based on RNA, although DNA-based viral nucleic acids are not uncommon. Virus genomes can be linear, circular, or segmented; single-stranded or double-stranded; positive-sense or negative-sense. And many viruses have high rates of mutation, such as point mutations, recombinations, or segment reassortments, that can render them resistant to antiviral treatments – or result in a new, more virulent strain when a major genetic change is involved.

So we offer next-generation sequencing solutions that can:

n Identify emerging viruses

n Study viral genomics and phylogeny

n Track mutations within viral genomes

n Determine human genetic variants impacting viral pathogenesis and case severity

n Identify disease-associated biomarkers, including those based on extracellular RNA

Read our blog post to learn more about using next-generation sequencing to help understand the epidemiology of SARS-Cov-2.

Our VICTOR® Nivo™ multimode plate reader is perfect for high-throughput DNA quantification for NGS – you can read about it here.

Join our webinar to learn more about the SARS-CoV-2 origins and adaptation in humans.

Check out this webinar to learn more about how SARS-CoV-2 adapts to environmental pressure and persists in infective action.

l

l

l

l

l

l

l

ll

l

STAYING AHEAD OF VIRUSESEXISTING AND EMERGINGDiscovery of new antiviral therapies is critical for global human health, particularly as new viruses such as the novel coronavirus or influenza viruses can emerge quickly. Standard drug discovery pipelines can take more than a decade to deliver a product to market. One way to accelerate therapeutic development, especially in times of high unmet medical crises such as SARS-CoV-2, is to repurpose existing drugs. But whether it’s for drug repurposing or discovery, detecting viruses in cell cultures and quantifying viral replication reliably are critical to fighting existing or emerging viruses.

We deliver detection, imaging, and automation solutions to:

n Determine viral titers using automated virus plaque imaging

n Discover new antiviral therapies with phenotypic or target-based screening

n Repurpose existing treatments against emerging viruses

n Monitor virus-induced cell toxicity or death

n Perform pseudovirus assays to identify inhibitors of host cell–receptor binding

n Measure virus neutralization with a variety of technologies (luminescence, fluorescence, plaque imaging)

We offer nucleic acid detection solutions to:

n Detect SARS-CoV-2 nucleic acids using RT-PCR

n Screen wastewater or environmental surfaces for the presence of SARS-CoV-2

Read our technical note to see how virus plaque imaging and analysis can be automated to reduce assay variability.

This blog post discusses the use of high-content imaging solutions to identify possible Zika virus inhibitors.

Here we explore how screening existing compounds approved to treat other conditions or diseases can provide ways to fight SARS-CoV-2.

Learn more about the technologies used to discover remdesivir, one of the few drugs available to treat COVID-19.

l

l

l

l

l

l

l

ll

l

UNDERSTANDINGHOST VIRAL MECHANISMSViruses replicate themselves through host cells, interacting with many different proteins. These protein-protein interactions (PPIs), known as the virus-host interactome, can be targeted with therapeutic drugs to inhibit viral infection or subsequent replication. Developing inhibitors against the virus-host interactome by targeting cellular proteins is a promising approach to circumventing possible emergence of drug-resistant virus mutants, as cellular proteins have much lower intrinsic mutation rates than viral proteins. Another way to decrease viral escape mutants is the development of antibody cocktails, a mix of neutralizing antibodies that target different epitopes on viral surface proteins.

We offer detection, imaging, and automation solutions to:

n Study host-virus interactions in physiologically relevant cell models

n Identify new drug targets using high-content screening

n Study the kinetics of host-cell infection using live-cell imaging

n Identify viral attachment inhibitors using homogenous assays such as Alpha or HTRF technologies

n Identify PPI inhibitors for various stages of the viral lifecycle

n Monitor host-pathogen interactions using in vivo imaging

Read how high-content imaging siRNA screens can help identify host cell factors essential for inhibiting alphavirus infections.

In this literature review, you’ll see what’s new in protein-protein interaction assays for virology research.

Read how our multimode plate readers, HCS systems, and microfluidics solutions contribute to the discovery of an antibody cocktail to fight SARS-CoV-2.

Check out this webinar to see how preclinical imaging is key to understanding viral and bacterial diseases and aiding development of new therapeutics and vaccines.

Learn how CT imaging quantified lung abnormalities in Syrian hamsters over a 14-day period after infection with SARS-CoV- 2.

l

l

l

l

l

l

l

ll

l

USING THE BODY’S OWN DEFENSES

TO FIGHT VIRUSESThe innate immune system is the body’s first line of defense against viral disease. Different cell types protect the host from infection by foreign agents in a nonspecific manner. If a pathogen overcomes this defense, the adaptive immune system is activated to produce antibodies and confer a long-lasting resistance. Neutralizing antibodies that prevent a pathogen from binding to its host cell receptor play a major role in fighting viral infections and are often the desired outcome of vaccination. To work in concert, immune cells communicate via ligand-receptor interactions that activate intracellular signaling pathways and secreted cytokines.

We offer detection and imaging solutions to:

n Measure virus neutralization using luminescence, fluorescence, or plaque imaging

n Detect the antiviral immune response – cytokines and protein phosphorylation

n Study cytokine storms by detecting IL-6, TNFα, and JAK/STAT signaling

n Analyze and QC DNA/RNA, protein, or viral particle-based vaccine candidates using electrophoresis

n Study TLR activation by adjuvants

n Understand the biology behind viral immune response using in vivo imaging

n Evaluate the efficacy, toxicity, and biodistribution of vaccines in small animals

See how pseudoviruses can help speed the development of a COVID-19 vaccine by mimicking the infectious process safely.

Learn how HCS supports three major strategies to fight viral diseases: drug repurposing, drug discovery and vaccines.

Learn how our microfluidics platform supports SARS-CoV-2 vaccine development.

Read our Immunology Guide, which can help researchers navigate the diversity of immune cell types and molecular pathways.

Read how to measure a STING binding using HTRF® cell-based assays to understand key signalling processes in innate immunity.

Learn how in vivo imaging using Neutrophil Elastase 680, a NIR fluorescent probe, can reveal the biology of neutrophilic response in respiratory infections.

Read how noninvasive optical imaging enables the most intricate host-pathogen interactions to be visualized and monitored in disease models.

l

l

l

l

l

l

l

ll

l

With all the advances in vaccine and therapeutics discovery and

development, we’re generating vast amounts of data. Making

sense of it all is perhaps the challenge of our time. So our

informatics solutions are designed to speed identification of

vaccine or therapeutic candidates; help you import, align, and

analyze biological sequences; and manage experimental,

instrument, and outsourced pharmacology data.

ELECTRONIC LAB NOTEBOOKS We offer ELNs to meet the needs of scientists and researchers, helping you organize and share experimental data efficiently and communicate

seamlessly with the common instruments and devices you use. Read More

LEAD DISCOVERY Our lead-discovery solutions provide a faster way to help chemists and virologists gain insights through a guided search and analysis workflow that

queries and represents data in intuitive, intelligent ways. Read More

DATA VISUALIZATION Our data visualization platform can empower your team or your entire organization to easily mine scientific and business data and gain insights, in

real time. You can create simple dashboard metrics, predictive applications, or dynamic real-time analytics applications with capabilities such as

visual, predictive, location, and streaming analytics; data wrangling; and much more. Read More

CLINICAL ANALYTICS Our solutions streamline clinical trials with real-time access to data during all phases of clinical development, allowing you to interact with

information as soon as it’s collected. You’re better able to explore key aspects of the protocol for specified follow-up, ensure adherence by

identifying drop-outs and violations, facilitate data cleaning and data quality, and much more. Read More

SMARTER QUESTIONSBETTER ANSWERS

l

l

l

l

l

l

l

ll

l

HIGH-THROUGHPUTNUCLEIC ACID ISOLATION

RADIOCHEMICALS AND RADIOMETRIC DETECTORS

MICROFLUIDIC DEVICES

MULTIMODE PLATE READERS

AUTOMATED LIQUID HANDLING

MICROPLATES

NGS LIBRARY PREP KITS

REAGENTS FOR VIROLOGY RESEARCH

DETECTION: Innovative, Integrated Solutions That Accelerate Your Workflow

GENOMICS: Automation Improves Workflow EfficiencyOur optimized, automated instruments and kits help you meet the challenges of genomics analysis with complete, single-source solutions – from sample to results.

Whether you’re assessing a virus candidate or monitoring an immune response, our instruments, assay technologies, and reagents provide simple, sensitive, streamlined workflows to accelerate research and development.

l

l

l

l

l

l

l

ll

l

HIGH-CONTENT IMAGING

OPTICAL IMAGING

LIVE-CELL IMAGING

MICRO-CT IMAGING

IMAGE ANALYSIS AND DATA SHARING

IN VIVO IMAGING REAGENTS

MICROPLATES FOR CELL IMAGING

IN VIVO IMAGING: The Power of Preclinical Imaging

CELLULAR IMAGING: Phenotype Cellular ResponsesTo help deepen our understanding of host-virus interactions or screening compound libraries to repurpose drugs or identify novel antiviral drugs, our cellular imaging solutions are proven, powerful tools for turning insights into discovery.

Whether you’re exploring viral immune responses or evaluating efficacy, toxicity, and biodistribution of a drug or vaccine candidate, our small-animal imaging tools can lead to your next big breakthrough.

l

l

l

l

l

l

l

ll

l

SARS-COV-2 NUCLEIC ACID DETECTION KIT (RUO)

SARS-COV-2 PCR DETECTION

JANUS® G3 WORKSTATIONS

SARS-COV-2 NEXT-GENERATION SEQUENCING

EXPLORER™ INTEGRATED RT-PCR WORKSTATIONS

WASTEWATER TESTINGENVIRONMENTAL SURFACE TESTING

SARS-COV-2 TESTING: When Science Is Mission Critical

SARS-COV-2 APPLICATIONS: Battling the Virus Everywhere

We work closely with laboratories around the world to provide the nucleic acid isolation, automation, real-time PCR, antibody testing, and vaccine develop-ment solutions to quickly respond to our most daunting challenges.

Ideal for studying SARS-CoV-2 in laboratory samples or testing in environmental samples, we deliver sensitive, reliable solutions to help you better address this most urgent public health concern.

l

l

l

l

l

l

l

ll

l

Most labs don’t maintain the in-house expertise needed to plan and

implement the types of projects that can transform chaotic lab

operations into the sleek, efficient, effective lab of the future. After

all, you should be concentrating on your core competency – your

science – and leaving the infrastructure, operations, and even lab

management to the professionals. That’s why so many smart labs

are looking to outsourcing to help them plan, design, deploy, and

manage their lab environments.

COMPUTER SYSTEM VALIDATION (CSV) CSV services range from full validation or commissioning for new systems to change-control validation for existing standalone and enterprise systems.

Our team follows GAMP 5 templates and aligns with your site’s policies and procedures as they relate to the software development lifecycle. At the

same time, we provide a range of software IQ/OQ offerings, including enhanced-security instrument software products. Read More

DATA INTEGRITY Many regulatory agencies have determined that electronic data is more secure than paper documentation and less likely to be manipulated over the

phases of a product’s development lifecycle. But that doesn’t mean electronic lab data is perfect: It must comply with other stringent regulations,

including 21 CFR Part 11 and the EDQM Annex 11. Read More

INSTRUMENT QUALIFICATION Our OneSource Instrument Qualification methods maximize your lab productivity while providing ongoing compliance capabilities. We guide your lab

through automated, secure electronic or traditional paper qualification procedures with standard recommended OQ protocols customized to your

specifications. Read More

GMP RADIOSYNTHESIS Our experienced chemists work with you to design and prepare your radiochemical to your exacting specifications. You have access to our extensive

technical support resources to help with protocol creation, custom synthesis of radioactive products, stability testing, special packaging, and analytical

services. Read More

EXPERT SERVICESWHEREVER YOU NEED THEM

For more information visit https://www.perkinelmer.com/category/viral-disease-research-therapeutic-development

For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs

Copyright ©2020, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc. All other trademarks are the property of their respective owners. 131478 PKI

PerkinElmer, Inc. 940 Winter Street Waltham, MA 02451 USA P: (800) 762-4000 or (+1) 203-925-4602www.perkinelmer.com